198 related articles for article (PubMed ID: 36398320)
21. Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.
Schwier NC
Ann Pharmacother; 2022 May; 56(5):572-581. PubMed ID: 34459270
[TBL] [Abstract][Full Text] [Related]
22. [Anti-interleukin-1 agents: a new class of drugs for recurrent pericarditis. A practical guide for cardiologists].
Imazio M; Lazaros G; Gattorno M; Abbate A; Brucato A
G Ital Cardiol (Rome); 2021 Oct; 22(10):833-843. PubMed ID: 34570117
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?
Picco P; Brisca G; Traverso F; Loy A; Gattorno M; Martini A
Arthritis Rheum; 2009 Jan; 60(1):264-8. PubMed ID: 19116906
[TBL] [Abstract][Full Text] [Related]
24. Clinical Trials in Pericardial Disease: New Paradigm Shift.
Imazio M
Curr Cardiol Rep; 2021 Oct; 23(11):170. PubMed ID: 34633515
[TBL] [Abstract][Full Text] [Related]
25. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD; Yalamanoglu A; Boyman O
Front Immunol; 2022; 13():888392. PubMed ID: 35874710
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?
Malcova H; Milota T; Strizova Z; Cebecauerova D; Striz I; Sediva A; Horvath R
Front Pharmacol; 2020; 11():619273. PubMed ID: 33708123
[TBL] [Abstract][Full Text] [Related]
27. Recurrent Pericarditis: a Stubborn Opponent Meets New Treatments in 2022.
Hagerty T; Kluge MA; LeWinter MM
Curr Cardiol Rep; 2022 Aug; 24(8):915-923. PubMed ID: 35612721
[TBL] [Abstract][Full Text] [Related]
28. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Klein AL; Imazio M; Cremer P; Brucato A; Abbate A; Fang F; Insalaco A; LeWinter M; Lewis BS; Lin D; Luis SA; Nicholls SJ; Pano A; Wheeler A; Paolini JF;
N Engl J Med; 2021 Jan; 384(1):31-41. PubMed ID: 33200890
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept.
Lin D; Klein A; Cella D; Beutler A; Fang F; Magestro M; Cremer P; LeWinter MM; Luis SA; Abbate A; Ertel A; Litcher-Kelly L; Klooster B; Paolini JF
BMC Cardiovasc Disord; 2021 Apr; 21(1):201. PubMed ID: 33882846
[TBL] [Abstract][Full Text] [Related]
30. Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety.
Correia ETO; Dos Santos Barbetta LM; de Almeida JPCL; Mesquita ET
J Cardiovasc Pharmacol; 2020 Jul; 76(1):42-49. PubMed ID: 32265370
[TBL] [Abstract][Full Text] [Related]
31. Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease.
Tomelleri A; Cavalli G; De Luca G; Campochiaro C; D'Aliberti T; Tresoldi M; Dagna L
Front Immunol; 2018; 9():1233. PubMed ID: 29910817
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY.
Brucato A; Lim-Watson MZ; Klein A; Imazio M; Cella D; Cremer P; LeWinter MM; Luis SA; Lin D; Lotan D; Pancrazi M; Trotta L; Klooster B; Litcher-Kelly L; Zou L; Magestro M; Wheeler A; Paolini JF;
J Am Heart Assoc; 2022 Oct; 11(20):e023252. PubMed ID: 36250662
[TBL] [Abstract][Full Text] [Related]
33. Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.
Emmi G; Urban ML; Imazio M; Gattorno M; Maestroni S; Lopalco G; Cantarini L; Prisco D; Brucato A
Curr Cardiol Rep; 2018 Jun; 20(8):61. PubMed ID: 29904899
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA
Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-1 blockade for the treatment of pericarditis.
Buckley LF; Viscusi MM; Van Tassell BW; Abbate A
Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):46-53. PubMed ID: 28633474
[TBL] [Abstract][Full Text] [Related]
36. Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis.
Wang TKM; Klein AL
Curr Cardiol Rep; 2022 Jan; 24(1):23-30. PubMed ID: 34993745
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis.
Jain S; Thongprayoon C; Espinosa RE; Hayes SN; Klarich KW; Cooper LT; Moder KG; Anavekar NS; Oh JK; Matteson EL
Am J Cardiol; 2015 Oct; 116(8):1277-9. PubMed ID: 26279106
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in pericarditis.
Bizzi E; Picchi C; Mastrangelo G; Imazio M; Brucato A
Eur J Intern Med; 2022 Jan; 95():24-31. PubMed ID: 34556390
[TBL] [Abstract][Full Text] [Related]
39. Goflikicept and Related IL-1 Inhibitors in the Treatment of Recurrent Pericarditis.
Feldman JM; Frishman WH; Aronow WS
Cardiol Rev; 2024 May; ():. PubMed ID: 38709249
[TBL] [Abstract][Full Text] [Related]
40. Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.
Imazio M; Klein AL; Brucato A; Abbate A; Arad M; Cremer PC; Insalaco A; LeWinter MM; Lewis BS; Lin D; Luis SA; Nicholls SJ; Sutej P; Wasserstrum Y; Clair J; Agarwal I; Wang S; Paolini JF;
J Am Heart Assoc; 2024 Mar; 13(6):e032516. PubMed ID: 38471825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
